Predicine Liquid Biopsy Outperforms Four Other Leading ctDNA NGS Tests in a Study by Bristol Myers Squibb
- Friday, May 13, 2022, 7:14
- PR Newswire
- Add a comment
SILICON VALLEY, Calif., May 13, 2022 /PRNewswire/ — Predicine, Inc., a global molecular insights company, today announced the results of a new research study that demonstrated superior performance of the PredicineATLAS™ liquid biopsy next-generation sequencing (NGS) assay compared to…
About the Author
admin has written 21729 stories on this site.